LPCN - Lipocine Inc.
| Previous Close | 2.8300 |
| Open | 2.7900 |
| Bid | 2.8000 x 800 |
| Ask | 2.8200 x 1100 |
| Day's Range | 2.7600 - 2.8450 |
| 52 Week Range | 1.0400 - 3.4500 |
| Volume | 40,685 |
| Avg. Volume | 149,753 |
| Market Cap | 70.309M |
| Beta (3Y Monthly) | 0.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
How Should Investors Feel About Lipocine Inc.'s (NASDAQ:LPCN) CEO Pay?
Mahesh Patel has been the CEO of Lipocine Inc. (NASDAQ:LPCN) since 1997. This report will, first, examine the CEO...
- Zacks Small Cap Research
LPCN: NASH Trial Launched
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Second Quarter 2019 Operational and Financial Results On August 7, 2019 Lipocine (NASDAQ:LPCN) filed its 2Q:19 10-Q and posted its ...
- Simply Wall St.
Is Lipocine (NASDAQ:LPCN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- Zacks Small Cap Research
LPCN: Poster Demonstrates NASH and Free T Link
While there has been evidence of a relationship between low free testosterone (T) levels and non-alcoholic steatohepatitis (NASH) as well as between fibrosis and non-alcoholic fatty liver disease (NAFLD), until recently it had not yet been supported by a biopsy confirmed study in humans. The authors of a recent poster, Sarkar, et al. did identify this relationship between low free T and NASH and between fibrosis and biopsy confirmed NAFLD enrolling adult men with a full spectrum of biopsy confirmed NAFLD.
- Simply Wall St.
What Percentage Of Lipocine Inc. (NASDAQ:LPCN) Shares Do Insiders Own?
A look at the shareholders of Lipocine Inc. (NASDAQ:LPCN) can tell us which group is most powerful. Institutions often...
- Benzinga
18 Stocks Joining The Russell Indices
The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...
- Simply Wall St.
Is Lipocine Inc.'s (NASDAQ:LPCN) Balance Sheet Strong Enough To Weather A Storm?
While small-cap stocks, such as Lipocine Inc. (NASDAQ:LPCN) with its market cap of US$32m, are popular for their...
- Zacks Small Cap Research
LPCN: Now We Have PDUFA Date; Target To $7
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT HERE First Quarter 2019 Operational and Financial Results On May 8, 2019 Lipocine (NASDAQ:LPCN) filed its 1Q:19 10-Q and posted ...
- Associated Press
Lipocine: 1Q Earnings Snapshot
The Salt Lake City-based company said it had a loss of 14 cents per share. The company's shares closed at $1.86. A year ago, they were trading at $1.57. _____ This story was generated by Automated Insights ...
- Simply Wall St.
Did You Manage To Avoid Lipocine's (NASDAQ:LPCN) Devastating 81% Share Price Drop?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While not a mind-blowing move, it is good to see that the Lipocine Inc. (NASDAQ:LPCN) share price...
- Zacks Small Cap Research
LPCN: Turning the Tables
During the approval of these competitors, Lipocine Inc. (LPCN) has been completing its blood pressure and ex vivo conversion studies in support of a 2Q:19 resubmission of its new drug application (NDA) so it can obtain approval and launch its own oral formulation of TRT. Clarus and Lipocine have been competing for the same market and also battling it out in the courts over patent conflicts. After the recent grant of Lipocine’s Priority Motion by the Patent Trial and Appeal Board (PTAB) and the adverse judgment against Clarus regarding the interference case, we see a low likelihood of a successful appeal by Clarus.
- Zacks Small Cap Research
LPCN: ABPM Study Topline Data
Lipocine (LPCN) distributed a press release yesterday announcing the completion of the Ambulatory Blood Pressure Monitoring (ABPM) clinical study and providing topline results. Blood pressure measurements were taken at baseline and at end of study with 118 subjects providing evaluable ABPM data. Results of the ABPM demonstrated a mean change of systolic blood pressure (SBP) of +3.82 mm Hg and diastolic blood pressure (DBP) of +1.20 mm Hg over the course of the study.
- Zacks Small Cap Research
LPCN: NASH Topline
By John Vandermosten, CFA NASDAQ:LPCN READ THE LATEST LPCN RESEARCH REPORT Lipocine (NASDAQ:LPCN) announced topline results from its non-alcoholic steatohepatitis (NASH) liver fat study demonstrating relative ...
- Benzinga
Lipocine Surges On Positive 16-Week Liver Imaging Study For Its NASH Candidate
Lipocine Inc (NASDAQ: LPCN ) is seeing some momentum Tuesday morning after the company reported results of a study evaluating its non-alcoholic steatohepatitis (NASH) candidate. What Happened Lipocine ...
- Simply Wall St.
Does Lipocine Inc.’s (NASDAQ:LPCN) CEO Pay Reflect Performance?
Mahesh Patel became the CEO of Lipocine Inc. (NASDAQ:LPCN) in 1997. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll considerRead More...
- Zacks Small Cap Research
LPCN: Soldiering on and Winning Some Battles
Lipocine (LPCN) published two press releases in the last two weeks signaling the advancement of LPCN 1144 towards a Phase II trial in non-alcoholic steatohepatitis (NASH) with biopsy confirmed NASH subjects. In the weeks prior, the company released other positive news regarding the grant of priority motion against Clarus and results from the phlebotomy study required to resubmit TLANDO.
- Benzinga
Lipocine's NASH Candidate Shows Promise In Liver Fat Study
Lipocine Inc (NASDAQ: LPCN ) shares were skyrocketing Thursday following the release of results from a study evaluating LPCN 1144, its pipeline asset for non-alcoholic steatohepatitis, or NASH. What Happened ...
- Zacks Small Cap Research
LPCN: Tlando Readouts Coming Soon; NDA to Follow
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT 3Q:18 Operational and Financial Results Lipocine (NASDAQ:LPCN) filed its 3Q:18 10-Q and posted its earnings release on November ...
- Simply Wall St.
Lipocine Inc (NASDAQ:LPCN): Are Analysts Optimistic?
Lipocine Inc’s (NASDAQ:LPCN): Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men’s and women’s health. The US$30m market-cap company’s loss lessens Read More...
- Associated Press
Lipocine: 3Q Earnings Snapshot
The Salt Lake City-based company said it had a loss of 12 cents per share. The company's shares closed at $1.50. A year ago, they were trading at $3.60. _____ This story was generated by Automated Insights ...
- Zacks Small Cap Research
LPCN: Androgen Therapy in NASH: A Comprehensive Approach
In their August 2018 corporate presentation, Lipocine Inc. (LPCN) announced the pursuit of a new indication in nonalcoholic steatohepatitis (NASH). The compound addressing this indication is designated LPCN 1144 and will be similar to the current Phase 3 candidate TLANDO, which has many characteristics that may contribute to the resolution of NASH. Prior to the announcement, Lipocine examined a library of literature supportive of androgens in the treatment of NASH and also reviewed its own clinical studies for TLANDO which provide evidence of efficacy for the drug on NASH biomarkers.
- Simply Wall St.
Do Institutions Own Shares In Lipocine Inc (NASDAQ:LPCN)?
The big shareholder groups in Lipocine Inc (NASDAQ:LPCN) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutionsRead More...
